Skip to content

TTRX TTRX Preferred Stock, Shares Authorized

Preferred Stock, Shares Authorized at other companies

Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
Arcutis Biotherapeutics, Inc. logo
Arcutis Biotherapeutics, Inc.ARQT
Tarsus Pharmaceuticals, Inc. logo
Tarsus Pharmaceuticals, Inc.TARS

Other financials

Income statement

See full
Operating income-$1.2M-224%
Net income-$971.0K-196%
EPS (diluted)-$0.03-200%

Balance sheet

See full
Cash & equivalents$11.2M+613%
Total debt$6.0M
Total equity$6.1M+647%
Total assets$18.6M

Cash flow

See full
Operating cash flow-$1.6M-448%

Valuation

See full
Market cap$217.45M-17.7%
Enterprise value$212.24M

Returns & leverage

See full
Return on equity-118.8%
Debt / equity
Current ratio2.2×

Where this comes from

Reported directly by TTRX in its filing.

Tagged under the XBRL concept us-gaap:PreferredStockSharesAuthorized.

The official record: TTRX’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about TTRX's preferred stock, shares authorized.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is TTRX's preferred stock, shares authorized?
TTRX (TTRX) reported preferred stock, shares authorized of $100M in Q1 2026.